Neela Paykel - Hyperfine Gen Officer
Insider
Neela Paykel is Gen Officer of Hyperfine
| Age | 53 |
| Phone | 866 796 6767 |
| Web | https://hyperfine.io |
Neela Paykel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Neela Paykel against Hyperfine stock is an integral part of due diligence when investing in Hyperfine. Neela Paykel insider activity provides valuable insight into whether Hyperfine is net buyers or sellers over its current business cycle. Note, Hyperfine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hyperfine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Neela Paykel over three months ago Disposition of 98250 shares by Neela Paykel of Hyperfine subject to Rule 16b-3 |
Hyperfine Management Efficiency
The company has return on total asset (ROA) of (0.3196) % which means that it has lost $0.3196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5393) %, meaning that it created substantial loss on money invested by shareholders. Hyperfine's management efficiency ratios could be used to measure how well Hyperfine manages its routine affairs as well as how well it operates its assets and liabilities.Hyperfine currently holds 269 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Hyperfine has a current ratio of 14.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Hyperfine's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Matthew Pigeon | Inogen Inc | N/A | |
| George Parr | Inogen Inc | 53 | |
| Brad Nagel | Electromed | N/A | |
| Andre Marquette | Neuropace | N/A | |
| David Colleran | Anika Therapeutics | 52 | |
| McAlister Marshall | Integer Holdings Corp | 51 | |
| Michael Hutchinson | LivaNova PLC | 54 | |
| Michael Favet | Neuropace | 54 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Marco Dolci | LivaNova PLC | 62 | |
| Mark Quick | Orthofix Medical | N/A | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| Mark Saxton | Neuropace | 59 | |
| Agnes Lee | Inogen Inc | N/A | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| John Glenn | Iradimed Co | 63 | |
| Bart Bracy | Anika Therapeutics | N/A | |
| Christopher Holland | Electromed | 55 | |
| Charles III | Anika Therapeutics | N/A | |
| Anne Nunes | Anika Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 |
Hyperfine Leadership Team
Elected by the shareholders, the Hyperfine's board of directors comprises two types of representatives: Hyperfine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hyperfine. The board's role is to monitor Hyperfine's management team and ensure that shareholders' interests are well served. Hyperfine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hyperfine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott White, Chief Officer | ||
| Neela Paykel, Gen Officer | ||
| Alok Gupta, Chief Officer | ||
| Thomas Teisseyre, Chief Officer | ||
| Dave Castiglioni, Chief Officer | ||
| Maria Sainz, President CEO | ||
| Brett Hale, CFO, Officer | ||
| Edmond MD, Chief Officer | ||
| Mark Hughes, VP Operations | ||
| Jonathan Rothberg, Founder Chairman | ||
| Khan MD, Chief Officer | ||
| Kyla JD, Chief Officer | ||
| MD FACR, Vice Affairs | ||
| Tom Teisseyre, Chief Officer |
Hyperfine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hyperfine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (3.01) % | ||||
| Current Valuation | 33.28 M | ||||
| Shares Outstanding | 62.4 M | ||||
| Shares Owned By Insiders | 8.70 % | ||||
| Shares Owned By Institutions | 21.99 % | ||||
| Number Of Shares Shorted | 2.14 M | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 4.97 X |
Additional Tools for Hyperfine Stock Analysis
When running Hyperfine's price analysis, check to measure Hyperfine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hyperfine is operating at the current time. Most of Hyperfine's value examination focuses on studying past and present price action to predict the probability of Hyperfine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hyperfine's price. Additionally, you may evaluate how the addition of Hyperfine to your portfolios can decrease your overall portfolio volatility.